TY - JOUR
T1 - Papulonodular mucinosis associated with systemic lupus erythematosus
T2 - Possible mechanisms of increased glycosaminoglycan accumulation
AU - Pandya, Amit G.
AU - Sontheimer, Richard D.
AU - Cockerell, Clay J.
AU - Takashima, Akira
AU - Piepkorn, Michael
N1 - Funding Information:
From the Department of Dermatology, University of Texas Southwest-ern Medical Center, Dallasa; and the Department of Medicine, Di-vision of Dermatology, University of Washington School of Medi-cine, Seattle.b Supported by National Institutes of Health grant IP30 AR41940. Accepted for publication Aug. 18, 1994. Reprint requests: Amit G. Pandya, MD, Department of Dermatology, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9069. Copyright @ 1995 by the American Academy of Dermatology, 0190-9622/95 $3.00 + 0 16/l/60024
PY - 1995/2
Y1 - 1995/2
N2 - Background: The mechanism for the production of papulonodular mucinosis in patients with lupus erythematosus (LE) is not known. Objective: Our purpose was to determine whether fibroblasts in a patient with LE and papulonodular mucinosis produced more mucin than normal fibroblasts and whether this mucin production could be stimulated by the patient's serum. Methods: Skin fibroblasts from a patient with systemic LE and massive papulonodular mucin deposition, as well as normal fibroblasts, were incubated in the presence of serum from the patient or from a healthy volunteer. The production of glycosaminoglycan by fibroblasts was analyzed. Results: Fibroblasts from the patient produced more glycosaminoglycan than did normal fibroblasts. Glycosaminoglycan production was increased in all cells when incubated in the presence of the patient's serum. Conclusion: Cutaneous mucin deposition in patients with papulonodular LE skin lesions is associated with increased glycosaminoglycan production by dermal fibroblasts. Our preliminary observations suggest glycosaminoglycan production by these fibroblasts appears to be stimulated by a factor, (or factors) in the patient's serum that is yet to be identified.
AB - Background: The mechanism for the production of papulonodular mucinosis in patients with lupus erythematosus (LE) is not known. Objective: Our purpose was to determine whether fibroblasts in a patient with LE and papulonodular mucinosis produced more mucin than normal fibroblasts and whether this mucin production could be stimulated by the patient's serum. Methods: Skin fibroblasts from a patient with systemic LE and massive papulonodular mucin deposition, as well as normal fibroblasts, were incubated in the presence of serum from the patient or from a healthy volunteer. The production of glycosaminoglycan by fibroblasts was analyzed. Results: Fibroblasts from the patient produced more glycosaminoglycan than did normal fibroblasts. Glycosaminoglycan production was increased in all cells when incubated in the presence of the patient's serum. Conclusion: Cutaneous mucin deposition in patients with papulonodular LE skin lesions is associated with increased glycosaminoglycan production by dermal fibroblasts. Our preliminary observations suggest glycosaminoglycan production by these fibroblasts appears to be stimulated by a factor, (or factors) in the patient's serum that is yet to be identified.
UR - http://www.scopus.com/inward/record.url?scp=0028869756&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028869756&partnerID=8YFLogxK
U2 - 10.1016/0190-9622(95)90126-4
DO - 10.1016/0190-9622(95)90126-4
M3 - Article
C2 - 7829703
AN - SCOPUS:0028869756
SN - 0190-9622
VL - 32
SP - 199
EP - 205
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 2 PART 1
ER -